Answers are grounded in this paper and cite their sources.
Evaluates CD34+ progenitor levels in peripheral blood for diagnosing pancytopenia, suggesting clinical utility.
OBJECTIVES: In healthy individuals, CD34+ stem cells are detectable in peripheral blood in relatively low and stable numbers. The clinical utility of peripheral blood CD34+ stem cell quantitation in the evaluation of pancytopenia has not been systematically studied. METHODS: We used a large archival clinical cohort (n = 154) of pediatric patients from our pediatric-only institution without a history of hematologic disorder or circulating blasts on morphology who underwent peripheral blood flow cytometric screening for any reason. Circulating CD34+ stem cells and total progenitors were quantified and correlated with clinical characteristics and outcomes. RESULTS: Patients ultimately diagnosed with aplastic anemia (n = 15) showed significantly decreased circulating progenitors compared with those with cytopenias of alternative causes, whereas patients with infectious, inflammatory, or other presumed reactive conditions often demonstrated larger CD34+ progenitor populations, consistent with preserved or responsive marrow function. Using receiver operating characteristic analysis, the optimal cutoff for %CD34+ progenitors was 0.0124%, which was rounded to 0.01% for clinical interpretability. CONCLUSIONS: These findings support the potential clinical utility of peripheral blood CD34+ quantitation in the diagnostic workup of pediatric pancytopenia.
No takes yet. Share an insight, caveat, or question.
Reiman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: